Evidence map›Paper›PMID 28607957›Full record

ArticleAdvances in radiation oncology

Analysis of patient outcomes following proton radiation therapy for retinoblastoma.

Kent W Mouw, Beow Y Yeap, Paul Caruso, Aaron Fay, Madhusmita Misra, Roshan V Sethi, Shannon M MacDonald, Yen-Lin Chen, Nancy J Tarbell, Torunn I Yock and 10 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Paediatric proton therapy.The British journal of radiology · 2020
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Kent W MouwDepartment of Radiation Oncology, Brigham & Women's Hospital, Dana-Farber Cancer Institute, Boston, MA.
Beow Y YeapDepartment of Medicine, Massachusetts General Hospital, Boston, MA.
Paul CarusoDepartment of Radiology, Massachusetts General Hospital, Boston, MA.
Aaron FayOphthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA.
Madhusmita MisraNeuroendocrine Unit and Pediatric Endocrine Unit, Massachusetts General Hospital, Boston, MA.
Roshan V SethiHarvard Radiation Oncology Program, Boston, MA.
Shannon M MacDonaldDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Yen-Lin ChenDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Nancy J TarbellDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Torunn I YockDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Suzanne K FreitagOphthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA.
John E MunzenriderDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Eric GrabowskiDepartment of Pediatrics, Massachusetts General Hospital, Boston, MA.
Michelle KatzDivision of Pediatric Endocrinology, Massachusetts General Hospital, Boston, MA.
Karen KuhlthauDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Dawn DeCastroGordon Weiss Schanzlin Vision Institute, San Diego, CA.
Gena HeidaryDepartment of Ophthalmology, Boston Children's Hospital, Boston, MA.
Jessica CiralskyDepartment of Ophthalmology, Weill Cornell Medical Center, New York City, NY.
Shizuo MukaiRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA.
Helen A ShihDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Massachusetts General Hospital · USMassachusetts Eye and Ear Infirmary · USBoston Children's Hospital · USBrigham and Women's Hospital · USCornell University · USGordon Schanzlin New Vision Institute · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
PROTON THERAPY RESEARCH AND TREATMENT CENTERC06CA059267 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GOITEIN, MICHAEL · 1992 to 1995
–
NCATS NIH HHS UL1 TR001102NCI NIH HHS C06 CA059267
6 · The paper itself

Abstract

purposeProton radiotherapy (PRT) is used in the treatment of retinoblastoma (RB) and has the potential to minimize exposure of normal tissue to radiation and thus decrease risk of toxicity and second malignancies. However, comprehensive analyses of long-term patient outcomes are not available.

methodsRB patients treated with PRT at our institution between 1986 and 2012 were invited to return for participation in a study designed to assess long-term outcomes. Enrolled patients underwent comprehensive analysis including oncologic, ophthalmic, endocrine, cephalometric, and quality of life (QOL) assessments.

resultsA total of 12 patients were enrolled in this study, and the average length of follow-up among enrolled patients was 12.9 years (range 4.8-22.2 years). All enrolled patients had bilateral disease, and the disease and visual outcomes for enrolled patients were similar to outcomes for all RB patients treated with PRT over the same time period at our institution. Endocrine evaluation revealed no growth abnormalities or hormonal deficiencies across the cohort. Based on MRI and external cephalometry, PRT was associated with less facial hypoplasia than enucleation. Patient and parent-proxy QOL assessments revealed that RB treatment did not appear to severely impact long-term QOL.

conclusionsIn addition to providing an opportunity for long-term disease control and functional eye preservation, PRT does not appear to be associated with unexpected late visual, endocrine, or QOL effects in this cohort.

Identifiers

PMID28607957
PMCPMC5465815
OpenAlexW2549924526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.